GOVERNANCE & TRANSPARENCY
Quality Control & RDI Policy
Equigerminal, S.A., operates within the framework of the 'One Health' concept, developing advanced molecular biology diagnostic services for veterinary medicine, with a strong commitment to quality and research, development, and innovation (RDI).
01 / REQUISITES
Core Corporate Commitments
01
Meeting and exceeding the needs and expectations of our clients and other stakeholders by delivering excellence in biotechnology.
02
Ensuring strict compliance with all applicable legal, regulatory, and standard requirements governing our laboratory workflows.
03
Continuously monitoring and systematically improving the effectiveness of our Quality and RDI Management Systems.
04
Fostering an internal culture of continuous training and high technical qualification across all scientific personnel.
05
Guaranteeing absolute ethics, confidentiality, impartiality, and operational independence in all laboratory results and procedures.
02 / HORIZON
Research, Development & Innovation Policy
RDI ACTIVE
Our research agenda is tightly integrated with corporate strategy, positioning Equigerminal at the frontier of veterinary biotechnology.
Our RDI management is tightly aligned with our corporate strategy, reinforcing our competitive edge and leadership in veterinary biotechnology. We drive progress through clear, measurable objectives:
β
Fostering creative freedom and active internal participation to generate innovative ideas.
β
Establishing high-impact partnerships with international entities in the scientific and technological ecosystem.
β
Maximizing the commercial value of our research, generating advanced knowledge, and securing strategic intellectual property.
03 / AUTHORITY
Certified Framework
The Board of Directors at Equigerminal guarantees that all structural conditionsβtechnological, human, and financialβare continuously provisioned to fulfill this policy. Our growth is anchored on the systematic execution of sustainable, certified value.